Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402853 | 0.83 | CYP2C19 (0.47) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4983143 | 0.81 | GABRA1 (0.46) | KDM4EALDH1A1HSD17B10MAPTMAPK1 | |
| SCHEMBL8547885 | 0.80 | MAPK1 (0.49) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL13978662 | 0.78 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL11370867 | 0.78 | MAPK1 (0.50) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4132400 | 0.76 | GABRA1 (0.40) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL17694444 | 0.76 | THRB (0.42) | KDM4EALDH1A1HSD17B10HPGDMTNR1A | |
| SCHEMBL11071612 | 0.76 | MEN1 (0.39) | KDM4EALDH1A1HPGDMTNR1AMAPT | |
| SCHEMBL29645124 | 0.76 | THRB (0.42) | KDM4EALDH1A1HSD17B10HPGDMTNR1A | |
| SCHEMBL10940633 | 0.76 | ALDH1A1 (0.56) | KDM4EALDH1A1HSD17B10HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802557-B1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2802557-B1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9187411-B2 | Leukotriene B4 antagonist compound | ELI LILLY AND COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187411-B2 | Leukotriene B4 antagonist compound | ELI LILLY AND COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187411-B2 | Leukotriene B4 antagonist compound | ELI LILLY AND COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140343151-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY | 2014-11-20 | — | — | US | disclosed |
| US-20140343151-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY | 2014-11-20 | — | — | US | disclosed |
| US-20140343151-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY | 2014-11-20 | — | — | US | disclosed |
| EP-2802557-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | Eli Lilly and Company (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106238-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106238-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343151-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | LTB4R2, LTB4R, LTA4H | KDM4E 3325/4885ALDH1A1 2170/4885HSD17B10 391/4885 |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | KDM4E 1637/4885ALDH1A1 91/4885HSD17B10 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.